Cipla To Acquire South Africa's Actor Pharma For $48.6 Million
Cipla Ltd.'s wholly-owned South African subsidiary—Cipla Medpro South Africa (Pty) Ltd.—entered into a binding term sheet to acquire a 100% stake in Actor Holdings (Pty) Ltd., a privately owned pharmaceutical company specialising in consumer health and generic medicine.
The consideration has been fixed at ZAR 900 million (approx. $48.6 million or around Rs 400 crore) in cash for 920 equity shares representing a 100% equity stake, according to the exchange filing dated Sept. 4.
This was a strategic acquisition for Cipla South Africa to unlock future growth opportunities and leverage cost synergies in the South African market, Cipla said in the filing.
The acquiree company—Actor Pharma—was founded in 2009 and is currently the fifth largest privately owned over-the-counter player in the South African private market. It specialises in OTC and generic medicine with established consumer brands and identified niche prescription markets in women's health, nasal, cough and cold, and baby and child, the filing said.
The proposed acquisition is subject to the signing of the share purchase agreement, which is expected within 14 days from the date of the binding term sheet.
The transaction is expected to be completed within a maximum period of four months from the date of signing the share purchase agreement.
It will also require approval from the South African Competition Commission.
Umang Vohra, global managing director and chief executive officer at Cipla, said, "This is in line with our strategy of strengthening our OTC and wellness portfolio."
According to Paul Miller, chief executive officer of Cipla South Africa, "This is a unique opportunity that helps to build Cipla's OTC portfolio, providing the business with a more balanced revenue contribution between the prescription and over-the-counter businesses and continue to provide additional quality medicines for consumers."
Actor Pharma's revenue for the last three years—FY23, FY22, and FY21—stood at ZAR 233.6 million ($2.6 million or around Rs 100 crore), ZAR 199.3 million ($10.8 million or around Rs 90 crore), and ZAR 154.4 million ($8.3 million or around Rs 70 crore), respectively.
Shares of Cipla closed 0.49% lower at Rs 1,238.90 apiece, as compared with a 0.37% rise in the benchmark Sensex.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.